TABLE OF CONTENTS
Volume 78, Issue 4 (October 2005)
Pharmacogenetics and Genomics |
Pharmacokinetics and Drug Disposition |
Pharmacodynamics and Drug Action |
Clinical Pharmacology Grand Rounds |
Letters to the Editor |
Notes of the American Society for Clinical Pharmacology and Therapeutics
Commentaries
Ethnic differences in statin disposition
Rommel G. Tirona PhD
Clin Pharmacol Ther 78: 311-316; doi:10.1016/j.clpt.2005.07.006
Genetic and nongenetic determinants of between-patient variability in the pharmacokinetics of mycophenolic acid
Dennis A. Hesselink MD and Teun van Gelder MD, PhD
Clin Pharmacol Ther 78: 317-321; doi:10.1016/j.clpt.2005.06.008
Confounding factors for sex differences in pharmacokinetics and pharmacodynamics: Focus on dosing regimen, dosage form, and formulation
Mei-Ling Chen PhD
Clin Pharmacol Ther 78: 322-329; doi:10.1016/j.clpt.2005.06.012
Pharmacogenetics and Genomics
Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment
Edmund Lee PhD, Stephen Ryan MD, Bruce Birmingham PhD, Julie Zalikowski MS, Ruth March PhD, Helen Ambrose PhD, Rachael Moore BSc, Caroline Lee PhD, Yusong Chen PhD and Dennis Schneck MD, PhD
Clin Pharmacol Ther 78: 330-341; doi:10.1016/j.clpt.2005.06.013
Effect of OATP1B1 (SLCO1B1) variant alleles on the pharmacokinetics of pitavastatin in healthy volunteers
Jae-Yong Chung MD, Joo-Youn Cho PhD, Kyung-Sang Yu MD, PhD, Jung-Ryul Kim MD, Dal-Seok Oh OMD, Hye-Ryung Jung MS, Kyoung-Soo Lim MD, Ki-Ho Moon, Sang-Goo Shin MD, PhD and In-Jin Jang MD, PhD
Clin Pharmacol Ther 78: 342-350; doi:10.1016/j.clpt.2005.07.003
The impact of uridine diphosphate–glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T—275A and C—2152T on early mycophenolic acid dose-interval exposure in de novo renal allograft recipients
Dirk R. J. Kuypers MD, PhD, Maarten Naesens MD, Severine Vermeire PhD and Yves Vanrenterghem MD, PhD
Clin Pharmacol Ther 78: 351-361; doi:10.1016/j.clpt.2005.06.007
Influence of CYP2C9 genotypes on the pharmacokinetics and pharmacodynamics of piroxicam
Jamila A. Perini PharmD, Rosane Vianna-Jorge PharmD, PhD, Ariane R. Brogliato and Guilherme Suarez-Kurtz MD, Doct Med
Clin Pharmacol Ther 78: 362-369; doi:10.1016/j.clpt.2005.06.014
CYP2C9, but not CYP2C19, polymorphisms affect the pharmacokinetics and pharmacodynamics of glyburide in Chinese subjects
Ophelia Q.P. Yin PhD, Brian Tomlinson MD and Moses S.S. Chow PharmD
Clin Pharmacol Ther 78: 370-377; doi:10.1016/j.clpt.2005.06.006
Impact of CYP2D6 genotype on adverse effects during treatment with metoprolol: A prospective clinical study
Richard Fux MD, Klaus Mörike MD, Anne M.T. Pröhmer MD, Ursula Delabar PhD, Matthias Schwab MD, Elke Schaeffeler PhD, Gernot Lorenz MD, Christoph H. Gleiter MD, Michel Eichelbaum MD and Kari T. Kivistö MD
Clin Pharmacol Ther 78: 378-387; doi:10.1016/j.clpt.2005.07.004
Cyclosporine markedly raises the plasma concentrations of repaglinide
Lauri I. Kajosaari MB, Mikko Niemi MD, Mikko Neuvonen MSc, Jouko Laitila, Pertti J. Neuvonen MD and Janne T. Backman MD
Clin Pharmacol Ther 78: 388-399; doi:10.1016/j.clpt.2005.07.005
Pharmacokinetics and Drug Disposition
Oral contraceptives containing ethinyl estradiol and gestodene markedly increase plasma concentrations and effects of tizanidine by inhibiting cytochrome P450 1A2
Marika T. Granfors MB, Janne T. Backman MD, Jouko Laitila and Pertti J. Neuvonen MD
Clin Pharmacol Ther 78: 400-411; doi:10.1016/j.clpt.2005.06.009
Pharmacodynamics and Drug Action
Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor
Dagmar Kubitza MD, Michael Becka PhD, Barbara Voith PhD, Michael Zuehlsdorf PhD and Georg Wensing MD
Clin Pharmacol Ther 78: 412-421; doi:10.1016/j.clpt.2005.06.011
Glutathione peroxidase, thioredoxin, and membrane protein changes in erythrocytes predict ribavirin-induced anemia
Ignazio Grattagliano MD, Stefan Russmann MD, Vincenzo O. Palmieri MD, Piero Portincasa MD, PhD, Giuseppe Palasciano MD and Bernhard H. Lauterburg MD
Clin Pharmacol Ther 78: 422-432; doi:10.1016/j.clpt.2005.07.002
Clinical Pharmacology Grand Rounds
Imatinib induces hypothyroidism in patients receiving levothyroxine
Jan Willem B. de Groot MD, Bernard A. Zonnenberg MD, John T. M. Plukker MD, PhD, Winette T. A. van Der Graaf MD, PhD and Thera P. Links MD, PhD
Clin Pharmacol Ther 78: 433-438; doi:10.1016/j.clpt.2005.06.010
Letters to the Editor
Informed consent or acknowledgment of disclosure
Marcus M. Reidenberg MD
Clin Pharmacol Ther 78: 439-440; doi:10.1016/j.clpt.2005.07.008
Additional discussions regarding the altered metabolism and transport of omeprazole after long-term use of St John's wort
Hong-Guang Xie MD, PhD
Clin Pharmacol Ther 78: 440-441; doi:10.1016/j.clpt.2005.07.009
The CYP2C9 genotype does not influence sildenafil pharmacokinetics in healthy volunteers
Alexander Jetter MD, Andreas Lazar MD, Edgar Schömig MD, Uwe Fuhr MD, Martina Kinzig-Schippers PhD and Fritz Sörgel PhD
Clin Pharmacol Ther 78: 441-443; doi:10.1016/j.clpt.2005.08.005
